Posted by Michael Wonder on 22 May 2024
The National Advisory Committee on Immunization recommends Beyfortus to protect all infants against RSV
21 May 2024 - The National Advisory Committee on Immunization issued a recommendation for Beyfortus (nirsevimab) to be used for the prevention of respiratory syncytial virus infection.
The committee has presented two strong recommendations for the delivery of Beyfortus to all Canadian infants that could be implemented through established systems and programs.
